What is First Ascent Biomedical?
First Ascent Biomedical is at the forefront of personalized cancer treatment, leveraging its proprietary drug prediction platform, DxPP. This advanced AI-driven technology, combined with expertise in therapy-resistant cell mechanisms, empowers oncologists with highly individualized treatment planning and accelerates drug development pipelines. The platform integrates functional drug testing, DNA/RNA sequencing, and AI-guided tumor mapping to deliver tailored therapeutic solutions for advanced cancer patients, offering a rapid 10-day turnaround for critical treatment decisions.
How much funding has First Ascent Biomedical raised?
First Ascent Biomedical has raised a total of $8M across 2 funding rounds:
Other Financing Round
$6M
Grant
$2M
Other Financing Round (2025): $6M with participation from Techstars
Grant (2025): $2M led by State of Florida - Department of Health
Key Investors in First Ascent Biomedical
Techstars
Techstars is a global investment firm and accelerator known for supporting early-stage technology startups. Their involvement suggests a belief in First Ascent Biomedical's innovative technology and potential for high growth in the biotech sector.
State of Florida - Department of Health
The State of Florida - Department of Health provides funding and support for health initiatives within the state. Their participation indicates alignment with public health goals and the potential impact of First Ascent Biomedical's technology on patient outcomes.
What's next for First Ascent Biomedical?
With the recent influx of major strategic investment, First Ascent Biomedical is poised for significant expansion and further development of its groundbreaking DxPP platform. This enterprise-level backing suggests a strategic focus on scaling operations, enhancing AI capabilities, and potentially forging new partnerships within the oncology and drug development ecosystems. The company's trajectory indicates a commitment to revolutionizing cancer treatment through precision medicine and data-driven therapeutic strategies, aiming to solidify its position as a leader in the fight against cancer.
See full First Ascent Biomedical company page
